Should You Subscribe to the IPO of BillionToOne Inc?

The Offer

Company Overview

BillionToOne Inc. (BLLN) is a pioneering biotechnology company transforming molecular diagnostics through its proprietary single-molecule next-generation sequencing (smNGS) platform, which enables ultra-precise detection and quantification of genetic material at the single-DNA-molecule level—overcoming the limitations of conventional sequencing technologies. The company’s Quantitative Counting Template (QCT) technology allows unprecedented sensitivity and accuracy, empowering a new generation of non-invasive diagnostics across prenatal and oncology applications. Its flagship prenatal product, UNITY, is the first non-invasive prenatal test (NIPT) capable of assessing fetal risk for recessive conditions such as sickle cell disease and cystic fibrosis using only maternal blood, establishing BLLN as a leader in genetic screening. In oncology, BillionToOne’s Northstar Select and Northstar Response liquid biopsy tests offer unmatched precision in mutation detection and real-time tumor burden monitoring, setting new standards for personalized cancer care.

Key Highlights

Primary Offering:

3,846,000 shares (underwriters an option to purchase up to 576,900 additional shares of Class A common stock).

Use of proceeds:

• Estimated Proceeds and Financial Impact: BillionToOne Inc. (BLLN) expects to generate approximately USD 180.4 million in net proceeds from its initial public offering, based on an assumed price of USD 52.00 per share, or up to USD 208.3 million if underwriters fully exercise their option to purchase additional shares. The company notes that for every USD 1.00 change in the offering price, net proceeds would vary by approximately USD 3.6 million, while a change of 1.0 million shares offered would alter proceeds by USD 48.4 million. These funds are anticipated to enhance BLLN’s financial flexibility, increase market visibility, and establish a public trading platform for its Class A common stock, strengthening its capital structure for strategic growth initiatives.
• Intended Use of Proceeds and Strategic Flexibility: The company plans to utilize the proceeds primarily for working capital, research and development, technology advancement, and general corporate purposes, including operating expenses and business expansion. A portion of the funds may also be allocated toward potential acquisitions or investments in complementary technologies or businesses to enhance its innovation pipeline. Management emphasizes that specific allocation of proceeds remains flexible and subject to evolving business conditions, providing the company discretion to adapt capital deployment as strategic opportunities arise. Until fully deployed, proceeds will be temporarily invested in short-term, investment-grade securities or government instruments, ensuring liquidity while maintaining a prudent financial position.

Dividend policy:

 BillionToOne Inc. (BLLN) has never declared or paid dividends and does not plan to distribute cash dividends on its Class A or Class B common stock in the foreseeable future, opting instead to reinvest earnings to fuel business growth and development. Any future dividend decisions will rest with the Board of Directors and will depend on the company’s financial condition, performance, and contractual restrictions, including those under existing and potential credit agreements.

Industry Background & Market Opportunity

• The Strengths and Challenges of Precision-Based Diagnostic Solutions: Precision diagnostics has revolutionized healthcare by enabling the detection of actionable biomarkers that guide accurate disease diagnosis and treatment across multiple therapeutic areas. Traditional methods, such as invasive sampling from fetal or tumor tissue, have given way to cell-free DNA (cfDNA) diagnostics, which offer non-invasive insights into genetic and epigenetic characteristics. However, the inherent scarcity of cfDNA — with fetal or tumor fragments often comprising less than 1% of total cfDNA — presents technical hurdles for reliable detection and quantification. Amplification processes required for analysis can introduce errors and biases, complicating the interpretation of results. Thus, while precision diagnostics offer immense clinical promise, they also demand advanced sequencing technologies capable of overcoming these inherent biological and technical limitations.
• Strategic Market Entry and Expansion in Prenatal and Oncology Applications: BillionToOne strategically leveraged its single-molecule next-generation sequencing (smNGS) platform to address these diagnostic challenges, initially disrupting the non-invasive prenatal testing (NIPT) market. By extending NIPT beyond chromosomal abnormalities to single-gene disorders such as cystic fibrosis and sickle cell disease, the company achieved substantial traction, becoming the second-largest prenatal genetics laboratory in the United States with 83% annual revenue growth. Building on this success, the company entered oncology diagnostics with its Northstar Select and Northstar Response tests, targeting therapy selection and real-time monitoring in late-stage cancer patients. With an estimated USD 100 billion total addressable oncology market, BillionToOne aims to expand its presence through next-generation products like tissue-free minimal residual disease (MRD) and early cancer detection tests, leveraging its smNGS technology to drive ultra-sensitive, tissue-independent diagnostics.
• Unmet Needs and the Rising Demand for Comprehensive Diagnostic Solutions: In prenatal care, approximately one in every 33 U.S. infants is born with congenital anomalies, many stemming from single-gene disorders that traditional cfDNA tests fail to detect. BillionToOne’s approach addresses this diagnostic gap by enabling comprehensive, non-invasive screening for high-risk conditions — significantly improving clinical decision-making and neonatal outcomes. Furthermore, its partnership with Johnson & Johnson underscores the clinical and commercial value of its technology, contributing companion diagnostics for the nipocalimab therapy in hemolytic disease of the fetus and newborn (HDFN). In oncology, the company’s Northstar platform offers transformative potential through methylation-based liquid biopsy tests that can detect tumor burden and therapeutic response months ahead of imaging scans. By advancing high-sensitivity cfDNA analytics across both prenatal and oncology markets, BillionToOne is effectively reshaping the landscape of precision diagnostics and establishing a robust foundation for future leadership in personalized medicine.

Financial Highlights (Results of Operations) (Expressed in USD)

• Business Model & Growth Trajectory: BLLN generates revenue by performing physician-ordered molecular diagnostic tests and billing insurers and/or patients upon result delivery. Commercializing prenatal tests in 2019 and oncology tests in early 2023, revenue scaled from USD 8.1M (2021) to USD 152.6M (2024) (+113% YoY in 2024) and rose a further 82% YoY in 1H25, driven by a 52% increase in tests processed and a 22% uplift in overall average selling price (ASP).
• Volume–ASP Flywheel & Reimbursement Levers: Test volumes and ASPs reinforce each other: higher volumes facilitate in-network contracts, lowering denials and improving economics; broader payer coverage and product-specific PLA codes (e.g., prenatal panel, Northstar Select/Response) further raise ASPs. 1H25 ASP gains reflected new payer contracts, higher reimbursement via proprietary codes, greater attachment of the 22q test and expanded RhD coverage, initial Medicare reimbursement for Northstar Select, and first-time billing for Northstar Response.
• Margin Expansion & Operating Efficiency: Cost of revenue rose 29% in 1H25 on higher volumes and labor/supply costs, but gross profit increased 133%, lifting gross margin from 51% (1H24) to 65% (1H25); approximately 72% of the margin improvement came from ASP increases and 28% from lower overall cost per test (54% of COGS variable; 56% of the cost-per-test improvement from variable cost reductions). Operational automation/AI, lab workflow optimization, and scale efficiencies narrowed net losses (USD 82.7M in 2023 to USD 41.6M in 2024), with management prioritizing sustained volume growth and continued ASP/COGS gains to further improve profitability.

Key Management Highlights

Risk Associated (High)

Investment in the IPO of “BLLN” is exposed to a variety of risks such as:

• Reimbursement and payer-coverage risk: A large portion of BLLN’s revenue depends on third-party payors (commercial insurers, Medicare/Medicaid) accepting and reimbursing its tests, including obtaining and maintaining favorable procedural codes and entering in-network contracts. If coverage is delayed, denied, or reimbursement rates remain below expectations, product uptake, average selling prices (ASPs), and margins could suffer significantly.
• Technology adoption and clinical validation risk: BLLN’s business is built on its proprietary single-molecule next-generation sequencing (smNGS) platform and assays such as prenatal and oncology liquid-biopsy tests. The success of these products hinges on widespread clinical adoption, demonstrated utility, guideline inclusion, and competitive differentiation. If competitors advance faster, validation is delayed, or clinical/market acceptance lags, growth may stall.
• Operational scalability and cost-control risk: The company is rapidly scaling test volumes to drive its “volume × ASP” flywheel and improve margins (gross margin already improved from 51% to 65% in six months). However, rapid growth requires continued investments in sales force, lab capacity, automation, and R&D. If cost per test does not decline as projected, infrastructure constraints emerge, or fixed-cost burdens rise faster than revenue, profitability and cash flow could be adversely impacted.

Conclusion

BillionToOne Inc. (BLLN) presents a compelling investment case for its IPO, given its strong technological edge, robust growth trajectory, and expanding market opportunity. The company’s proprietary single-molecule next-generation sequencing (smNGS) platform and Quantitative Counting Template (QCT) technology enable unparalleled sensitivity and accuracy in molecular diagnostics, positioning it as a frontrunner in non-invasive prenatal testing (NIPT) and precision oncology. With flagship products such as UNITY and Northstar Select/Response, BLLN has demonstrated significant commercial traction—achieving 113% revenue growth in 2024 and 82% in 1H25—supported by its “volume–ASP flywheel,” improved reimbursement coverage, and operational efficiency that lifted gross margins to 65%. The planned IPO proceeds of approximately USD 180 million will further enhance liquidity and fund continued innovation and expansion across its USD 100 billion addressable market. While reimbursement, adoption, and scalability risks persist, BLLN’s proven product performance, accelerating profitability trends, and leadership in high-growth precision diagnostics make it a promising long-term investment opportunity in the evolving healthcare technology landscape.

Hence, given the financial performance of the company, use of proceeds, and associated risks “BillionToOne Inc. (BLLN)” IPO seems “Attractive" at the IPO price.